Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb:210:105495.
doi: 10.1016/j.antiviral.2022.105495. Epub 2022 Dec 22.

A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships

Olivia Goethals  1 , Natalia V Voge  2 , Bart Kesteleyn  3 , Patrick Chaltin  4 , Tim Jinks  5 , Tine De Marez  6 , Anil Koul  1 , Ruxandra Draghia-Akli  2 , Johan Neyts  7 , Marnix Van Loock  8
Affiliations
Review

A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships

Olivia Goethals et al. Antiviral Res. 2023 Feb.

Abstract

While progress has been made in fighting diseases disproportionally affecting underserved populations, unmet medical needs persist for many neglected tropical diseases. The World Health Organization has encouraged strong public-private partnerships to address this issue and several public and private organizations have set an example in the past showing a strong commitment to combat these diseases. Pharmaceutical companies are contributing in different ways to address the imbalance in research efforts. With this review, we exemplify the role of a public-private partnership in research and development by the journey of our dengue antiviral molecule that is now in early clinical development. We detail the different steps of drug development and outline the contribution of each partner to this process. Years of intensive collaboration resulted in the identification of two antiviral compounds, JNJ-A07 and JNJ-1802, the latter of which has advanced to clinical development.

Keywords: Dengue antiviral research and development; Public-private partnership.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest O. G., N. V., B. K., T. D. M., A. K., M.V.L. are all full-time employees of Janssen and potential stockholder of Johnson and Johnson. Some of the authors are named inventors in patent applications relating to the dengue virus replication inhibitors described in the article. The other authors declare no financial or competing interests.

Figures

Fig. 1
Fig. 1
Overview of the contribution of each partner to the partnership.
See this image and copyright information in PMC

References

    1. Ackaert O., Vanhoutte F., Verpoorten N., Buelens A., Lachau-Durand S., Lammens L., Van Loock M., Herrera-Taracena G. The 70th American Society of Tropical Medicine & Hygiene (ASTMH) Annual Meeting, November 17-21, 2021, Virtual Meeting. 2021. Safety, tolerability and pharmacokinetics of a novel pan-serotyp dengue antiviral small molecule in a phase 1, double-blind, randomized, dose-escalation study.https://www.astmh.org/getmedia/59a95de8-1a06-49ca-9fd0-286454cc241a/ASTM... Presented at: Abstract 0582.
    1. Aerts C., Barrenho E., Miraldo M., Sicuri E. The impact of the priority review voucher on research and development for tropical diseases. Pharmaceut. Med. 2022;36:189–197. - PMC - PubMed
    1. Aerts C., Sunyoto T., Tediosi F., Sicuri E. Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature. Health Pol. 2017;121:745–754. - PubMed
    1. Akinokun R.T., Ilesanmi E.B., Adebisi Y.A., Akingbade O. The status of neglected tropical diseases amidst covid-19 in africa: current evidence and recommendations. Health Promot. Perspect. 2021;11:430–433. - PMC - PubMed
    1. Bill, Melinda Gates Foundation . 2022. Neglected Tropical Diseases.https://www.gatesfoundation.org/our-work/programs/global-health/neglecte...

Publication types

Substances